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Abstract: Cardiovascular disease (CVD) is the main cause of death worldwide, and aging is its leading
risk factor. Aging is much accelerated in Hutchinson–Gilford progeria syndrome (HGPS), an ultra-rare
genetic disorder provoked by the ubiquitous expression of a mutant protein called progerin. HGPS
patients die in their teens, primarily due to cardiovascular complications. The primary causes of
age-associated CVD are endothelial dysfunction and dysregulated vascular tone; however, their
contribution to progerin-induced CVD remains poorly characterized. In the present study, we found
that progeroid LmnaG609G/G609G mice with ubiquitous progerin expression show both endothelial
dysfunction and severe contractile impairment. To assess the relative contribution of specific vascular
cell types to these anomalies, we examined LmnaLCS/LCSTie2Cretg/+ and LmnaLCS/LCSSm22αCretg/+
mice, which express progerin specifically in endothelial cells (ECs) and vascular smooth muscle cells
(VSMCs), respectively. Whereas vessel contraction was impaired in mice with VSMC-specific progerin
expression, we observed no endothelial dysfunction in mice with progerin expression restricted to
VSMCs or ECs. Vascular tone regulation in progeroid mice was ameliorated by dietary sodium nitrite
supplementation. Our results identify VSMCs as the main cell type causing contractile impairment in
a mouse model of HGPS that is ameliorated by nitrite treatment.
Keywords: HGPS; progerin; VSMCs; ECs; vascular function; sodium nitrite
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide, in part due to progressive
aging, the main CVD risk factor [1]. A number of additional factors have been identified that increase
the risk of developing CVD, either acting alone or in combination (e.g., hypercholesterolemia, diabetes,
sedentary lifestyle, and smoking) [2–4]. However, studies on the effects of age alone (the only
factor we cannot modify or treat) remain scarce due to their high research costs associated with the
necessary long-term resource investment and delays in collecting results. The study of premature
aging syndromes characterized by accelerated CVD thus offers a unique opportunity to investigate
age-dependent drivers of CVD in the absence of other confounding risk factors [5,6].
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Hutchinson–Gilford progeria syndrome (HGPS, OMIM 176670) is a rare genetic disease
characterized by accelerated aging and death in adolescence [5–9]. HGPS children have impaired
postnatal growth, lipodystrophy, alopecia, pigmented and wrinkled skin, and skeletal dysplasia.
They also develop generalized atherosclerosis, arterial stiffness and calcification, electrocardiographic
abnormalities, and ventricular diastolic dysfunction and die prematurely at an average age of
14.6 years mainly due to myocardial infarction, stroke, or heart failure [7,10,11]. HGPS is caused by
a heterozygous de novo point mutation in the LMNA gene, which encodes the nuclear proteins lamin
A and C (A-type lamins) [12,13]. This synonymous mutation activates a cryptic splice donor site that
removes 150 nucleotides from exon 11, causing the synthesis of progerin [12,13]. This truncated form of
prelamin A is expressed ubiquitously and acts in a dominant-negative manner, causing alterations in
many essential nuclear functions, including nuclear structure, gene transcription, signal transduction,
DNA damage repair, chromatin organization, mechanosensing, and proliferation [14,15]. Aside from
its role in HGPS, progerin is detectable at low levels in several tissues during normal aging, including
atherosclerotic coronary arteries, suggesting a role in physiological aging [11,16–19].
Homozygous Lmna-null mice lacking A-type lamins develop to term without exhibiting overt
anomalies, but they develop skeletal muscle dystrophy and dilated cardiomyopathy soon after
birth and are all death by the eight week [20]. Interestingly, “Lamin C-Stop” mice (LCS) expressing
Lamin C but lacking lamin A are apparently normal, but are slightly heavier and longer-lived than
wild-type controls [21]. Over the last decade, several animal models of HGPS have been generated
and characterized [6,22]. LmnaG609G/G609G mice, which express ubiquously progerin and lamin C and
lack lamin A, recapitulate the main clinical manifestations of human HGPS, such as difficulty to thrive,
lipodystrophy, skeleton abnormalities, vascular calcification and stiffening, vascular smooth muscle cell
(VSMC) loss, and premature death [23–25]. Moreover, ubiquitous or VSMC-specific progerin expression
accelerates atherosclerosis in atherosclerosis-prone Apolipoprotein e-null mice (Apoe−/−), at least in part
due to excessive endoplasmic reticulum stress and associated unfolded protein response [26,27].
Vasomotor function is modulated by a delicate balance between constriction and dilation, which
are mainly controlled by luminal endothelial cells (ECs) and medial VSMCs [28–30]. The most
common pathological signs of vascular aging are endothelial dysfunction and vessel stiffness, which
can progress over the years to hypertension, cardiac and vessel overload, inflammation, fibrosis,
atherosclerosis, and heart failure [29–31]. The stiffness of aged vessels correlates with changes
in the mechanical properties of VSMCs, which lose their ability to contract when surrounded by
an abnormally stiff extracellular matrix [32,33]. Vessel stiffness is also a pathological signature
of HGPS [7,34], and progerin-expressing LmnaG609G/G609G mice exhibit altered vascular structure
characterized by stiffness and inward remodeling associated with VSMC degeneration and increased
collagen deposition in the medial layer [25]. In the present study, we investigated whether endothelial
dysfunction and defective regulation of vascular tone characterize progeroid LmnaG609G/G609G mice.
Moreover, to determine the relative contributions made by progerin-expressing ECs and VSMCs, we
bred LmnaLCS/LCS Tie2Cre+/tg and LmnaLCS/LCS SM22αCre+/tg mice, which express progerin specifically
in ECs and VSMCs respectively, but do not show any apparent signs of aging [25]. We also examined
the potential benefit of treatment with nitrites, a physiologically important storage form of nitric
oxide (NO) [35] that can partly revert vascular endothelial dysfunction and stiffness, oxidative stress,
and inflammation in physiological aging [36] and ameliorates structural stiffening in progeroid
mice [25].
2. Materials and Methods
2.1. Mice
All procedures with mice conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC,
enforced in Spanish law under Real Decreto 53/2013. Animal protocols were approved by the local
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ethics committees and the Animal Protection Area of the Comunidad Autónoma de Madrid (PROEX
135/14). Mice were housed at the CNIC pathogen free facility and sacrificed at 14–15 weeks of age.
Studies were carried out with males of the following genotypes (all on the C57BL/6J genetic
background): LmnaG609G/G609G mice with constitutive and ubiquitous progerin and lamin C expression
and lack of lamin A, obtained by crossing heterozygous LmnaG609G/+ males and females [23];
LmnaLCS/LCSSM22αCretg/+ mice with ubiquitous lamin C expression and VSMC-specific progerin
expression, obtained by crossing LmnaLCS/LCS mice [23] with SM22αCre+/− mice (The Jackson
Laboratory, Bar Harbor, ME, USA); LmnaLCS/LCSTie2Cretg/+ mice with ubiquituous expression of
lamin C and EC-specific progerin expression, obtained by crossing LmnaLCS/LCS mice with Tie2-Cre+/−
mice [37]. Controls for LmnaG609G/G609G mice were littermate wild-type mice expressing normal lamin
A/C (Lmna+/+), and controls for the VSMC- and EC-specific models were LmnaLCS/LCS littermates
expressing only Lamin C [23]. Specific expression of progerin in VSMCs and ECs was confirmed by
immunohistochemistry in aortic sections from LmnaLCS/LCSSM22αCretg/+ and LmnaLCS/LCSTie2Cretg/+
mice [25].
2.2. Nitrite Treatment
When indicated, 6-week-old LmnaG609G/G609G mice were treated for 8 weeks with sodium nitrite
(NaNO2, Sigma-Aldrich, St. Louis, MO, USA). The compound was dissolved in drinking water at
a final concentration of 50 mg/L, a dose that has been reported to be safe in mice, showing no evidence
of toxicological or carcinogenic effects and no effect on water consumption [38]. Consistent with
these findings, we observed no adverse effects or changes in water consumption in LmnaG609G/G609G or
Lmna+/+ mice treated with sodium nitrite.
2.3. Wire Myography
Animals were euthanized at 14–15 weeks of age by CO2 inhalation. Immediately after sacrifice,
the thoracic and abdominal cavities were opened. Thoracic aortas were excised and immediately
placed in ice-cold Krebs–Henseleit solution (KHS: 115 mM NaCl, 2.5 mM CaCl2, 4.6 mM KCl, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11.1 mM glucose, and 0.01 mM EDTA), gently cleaned
of fat and connective tissue, and cut into ~2 mm long segments. Aortic rings were then mounted on
2 tungsten wires in a wire myograph system (620M, Danish Myo Technology A/S, Hinnerup, Denmark)
and immersed in 37 ◦C KHS with constant gassing (95% O2 and 5% CO2). Wire myography was
performed as previously described [39]. Optimal vessel distension was determined by normalization
using the Laplace Equation (Tension = [pressure × radius]/thickness) to calculate the position at which
the tension was equivalent to an intraluminal pressure of 100 mmHg (L100) [39]; vessels were then set
up to the optimal tension (physiological distension, 0.9 of L100).
After equilibration for 30 min, vasoconstriction was studied by exposing the aortic rings first to
120 mM KCl and then to increasing doses of phenylephrine (from 1 nm to 10 µM; Sigma-Aldrich).
We assessed the contribution of vessel stiffness to the contractile function by analyzing contraction
induced by 120 mM KCl before and after collagen degradation with collagenase type II (0.2%
w/v, 15 min incubation; Thermo Fisher Scientific, Waltham, MA, USA). Endothelium-dependent
vasodilation was assessed by examining the response to increasing doses of acetylcholine (from
0.1 nM to 10 µM; Sigma-Aldrich) in segments previously contracted with 1 µM phenylephrine.
Endothelium-independent vasodilation induced by increasing doses of the NO donor diethylamine
NONOate (DEA-NO) (from 0.1 nM to 10 µM; Sigma-Aldrich) was examined in segments previously
contracted with 1 µM phenylephrine. Drug treatments were separated by extensive washes and
a stabilization period of at least 15 min. When indicated, the contribution of NO, Prostacilin I2 (PGI2),
H2O2, and O2− to endothelium-dependent vasodilation was assessed by adding the following agents
to the bath 30 min before the acetylcholine dose–response curve: 0.1 mM L-NAME (NOS inhibitor),
10 µM tranylcypromine (PGI2 inhibitor), 2000 U/mL catalase (H2O2 decomposing agent), and 0.1 mM
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Tempol (O2− scavenger) (all from Sigma-Aldrich). All drugs were dissolved in water except for the
Tempol stock solution, which was prepared in ethanol.
The results of wire myography experiments are represented as dose–response curves and as area
under the curve (AUC), which provides information regarding differences in the dose–response curve
as a whole and in a continuous manner.
2.4. Statistical Analysis
Results are represented as mean ± standard error of the media (SEM), and statistical differences
were analyzed using the tests indicated in the figure legends.
3. Results
3.1. Impaired Vascular Function in Progeroid Mice with Ubiquitous Progerin Expression
To investigate the impact of ubiquitous progerin expression on vascular function, we performed
ex vivo wire myography experiments to examine contraction and dilation in thoracic aorta segments
obtained from 14–15-week-old LmnaG609G/G609G mice and age-matched wild-type (Lmna+/+) littermate
controls. These studies demonstrated impaired contraction of progeroid vessel segments in response
to incubation with phenylephrine (Figure 1A) and KCl (Figure 1B).
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Figure 1. Defective aortic contraction in LmnaG609G/G609G mice. Thoracic aortas from 14-week-old 
progeroid LmnaG609G/G609G mice (ubiquitous progerin expression) and wild-type (Lmna+/+) mice were 
analyzed by wire myography (n = 12 for each genotype). (A) Strength of contraction induced by 
phenylephrine (left) and representation of the area under de curve (right; a.u.: arbitrary units). (B) 
Strength of contraction induced by KCl. Statistical differences were analyzed by two-way ANOVA 
with Bonferroni’s post-hoc test for phenylephrine data, and by two-tailed t-test for KCl data. * p < 0.05 
*** p < 0.001. 
To assess endothelial function, we first exposed phenylephrine-precontrated aortas to the 
endothelium-dependent vasodilator acetylcholine (Figure 2A). Relaxation induced by the 
physiological acetylcholine dose (0.1 µM) was significantly lower in LmnaG609G/G609G vessel segments, 
a result also evidenced by a difference in logEC50 (−7.025 ± 0.06 in Lmna+/+ aortic rings versus −6.511 
± 0.09 in LmnaG609G/G609G aortic rings) (Figure 2A, left) and a lower AUC for acetylcholine-induced 
relaxation (Figure 2A, right). In contrast, there were no significant differences in the relaxation of 
phenylephrine-precontrated Lmna+/+ and LmnaG609G/G609G aortic rings exposed to the endothelium-
independent vasodilator DEA-NO (Figure 2B). These results thus indicate that endothelial 
dysfunction underlies impaired vessel relaxation in mice with ubiquitous progerin expression. 
We next investigated which of the main factors contributing to acetylcholine-induced 
endothelial relaxation were altered in LmnaG609G/G609G aorta. For this, we prepared acetylcholine-
Figure 1. Defective aortic contraction in LmnaG609G/G609G mice. Thoracic aortas from 14-week-old
progeroid LmnaG609G/G609G mice (ubiquito s rogerin expression) an wild-type (Lmna+/+) mice were
analyzed by wire myography (n = 12 for ea enotype). (A) S rength of c ntraction induced by
phenylephrine (left) and representation of the area under de curve (right; a.u.: arbitrary units).
(B) Strength of contraction induced by KCl. Statistical differences were analyzed by two-way
ANOVA with Bonferroni’s post-hoc test for phenylephrine data, and by two-tailed t-test for KCl
data. * p < 0.05 *** p < 0.001.
To assess endothelial function, we first exposed phenylephrine-precontrated aortas to
the endothelium-dependent vasodilator acetylcholine (Figure 2A). Relaxation induced by the
physiological acetylcholine dose (0.1 µM) was significantly lower in LmnaG609G/G609G vessel
segments, result also evidenced by a differenc in logEC50 (−7.025 ± 0.06 in Lmna+/+ aortic
rings versus −6.511 ± 0.09 in LmnaG609G/G609G aortic rings) (Figure 2A, left) and a lower AUC for
acetylcholine-induced relaxation (Figure 2A, right). In contrast, there were no significant differences in
the relaxation of phenylephrine-precontrated L na+/+ and LmnaG609G/G609G aortic rings exposed to the
endothelium-independent vasodila or DEA-NO (Figure 2B). These results thus indicate that endothelial
dysfunction underlies impaired vessel relaxation in mice with ubiquitous progerin expression.
We next investigated which of the main factors contributing to acetylcholine-induced endothelial
relaxation were altered in LmnaG609G/G609G aorta. For this, we prepared acetylcholine-induced relaxation
curves in the presence of the following agents: L-NAME (NOS inhibitor), tranylcypromine (PGI2
synthase inhibitor), catalase (H2O2 decomposing agent), and Tempol (O2− scavenger). Significant
inhibition of acetylcholine-induced relaxation was observed only in L-NAME-treated Lmna+/+ and
LmnaG609G/G609G aortic rings; the other drugs had no significant effect irrespective of mouse genotype
(Figure 2C). These findings are consistent with the notion that NO is the main factor underlying
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endothelium-dependent acetylcholine-induced relaxation in vessels of both genotypes and suggest
that NO deficiency may account for the endothelial dysfunction in vessels of mice with ubiquitous
progerin expression.
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tranylcypromine (TCP), catalase, or Tempol. Statistical differences were analyzed by two-way 
ANOVA with Bonferroni’s post-hoc test for acetylcholine and DEA-NO data, and by one-way 
ANOVA for AUC data. * p < 0.05 and ** p < 0.01 compared with corresponding control in (A) and (C); 
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Figure 2. Defective endothelium-dependent aortic dilation in LmnaG609G/G609G mice. Thoracic aortas
from 14-week-old progeroid LmnaG609G/G609G mice (ubiquitous progerin expression) and wild-type mice
(Lmna+/+) were analyzed by wire myography (n = 12 for each genotype). (A) Endothelium-dependent
vasodilation induced by acetylcholine (left) and r presentation of the area under the curve
(AUC; a.u.: arbitrary units) (right). (B) Endothelium-independent vasodilation induced by the
NO donor diethylamine NONOate (DEA-NO). (C) Representation of area under the curve from
acetylcholine-dependent relaxation curves performed in the absence (control) or presence of L-NAME,
tranylcypromine (TCP), catalase, or Tempol. Statistical differences were analyzed by two- ANOVA
with Bonferroni’s post-hoc test for acetylcholine and DEA-NO data, and by one-way NOVA for AUC
data. * p < 0.05 and ** p < 0.01 compared with corresponding control in (A) and (C); +, p < 0.05 Lmna+/+
versus LmnaG609G/G609G in (C).
3.2. VSMC-Specific Progerin Expression Provokes Contractile Impairment, but Neither VSMC-Specific nor
EC-Specific Expression Is Sufficient to Cause Endothelial Dysfunction
VSMCs and ECs are key cellular co ponents of the vessel wall that play major oles in the
regulation of vascular tone. To determine the relative contribution of these cell types to impaired
vascular tone regulation in progeroid mice, we performed wire myography experiments in aortic
rings isolated from LmnaLCS/LCSSM22αCretg/+ and LmnaLCS/LCSTie2Cretg/+ mice, which express progerin
predominantly in VSMCs and ECs, respectively [25]. Controls for both models were LmnaLCS/LCS
littermates that do not express progerin [23]. Contraction in response to phenylephrine or KCl was
significantly lower in aortic rings from mice with VSMC-specific progerin expression (Figure 3A), like
in aortas from LmnaG609G/G609G mice with ubiquous progerin expression (cf. Figure 1A). In contrast,
aortas expressing progerin only in ECs contracted normally when incubated with phenylephrine or KCl
(Figure 3C). Likewise, vasodilation induced by either acetylcholine or DEA-NO was not significantly
different from controls in LmnaLCS/LCSSM22αCretg/+ (Figure 3B) or LmnaLCS/LCSTie2Cretg/+ aortic rings
(Figure 3D). These results demonstrate that smooth muscle, not endothelium, is the main vascular
cell type driving contractile impairment in progeroid mice and suggest that progeroid endothelial
dysfunction requires simultaneous expression of progerin in VSMCs and ECs.
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VSMCs (LmnaL S/LCSSM22αtg/+) or in ECs (LmnaLCS/LCSTie2tg/+) and in control mice without progerin
expression (LmnaLCS/LCS). (A) Contraction induced by phenylephrine (left) and KCl (right) in aortic rings
from LmnaLCS/LCSSM22αtg/+ mice and LmnaLCS/LCS controls. (B) Endothelium-depen ent vasodilation
induced by acetylcholine (left) and endothelium-independent vasodil tion induced by diethylamine
NONOate (DEA-NO) (right) in aortic rings from LmnaLCS/LCSSM22αtg/+ mice and LmnaLCS/LCS controls.
(C) Contraction induced by phenylephrine (left) and KCl (right) in aortic rings from LmnaLCS/LCSTie2tg/+
mice and LmnaLCS/LCS controls. (D) Endothelium-dependent vasodilation induced by acetylcholine
(left) and endothelium-independent vasodilati induced by DEA-NO (right) in aortic rings from
LmnaLCS/LCSTie2tg/+ mice and LmnaLCS/LCS controls. Statistical differences were analyzed by two-way
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two-tailed t-test for KCl data. * p < 0.05; *** p < 0.001.
We next tested whether m chanical m ediment by the stiff extracellular c ll matrix might
contribute t contractile impairment in progeroid mice. Since collagen deposition has been shown
to cause aortic stiffness in progeroid LmnaG609G/G609G mice [25], we examined KCl-induced aortic
contractions before and after collagen disruption with collagenase. Treatment with collagenase
did not improve KCl-induced aortic contraction in LmnaG609G/G609G and LmnaLCS/LCSSM22αtg/+ mice
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relaxation in progerid or control mice (Figure 5B, cf. Figure 2B). Nitrite treatment also ameliorated 
the impaired phenylephrine-dependent contraction in aortic rings from progeroid mice (Figure 5C, 
cf. Figure 1A). In contrast, nitrite treatment did not normalize KCl-induced contraction, which 
remained significantly lower in progeroid aortic rings control aortic rings than in vessels from Lmna+/+ 
controls (Figure 5B, cf. Figure 1B). These results demonstrate that dietary supplementation with 
sodium nitrite can ameliorate defective vascular tone regulation in progeroid mice. 
Figure 4. Collagen disruption by collagenase does not rescue contractile impairment in
progerin-e e sing mice. Wire myography experimen s to t st the effect of 15 min incubation with
0.2% collagenase on contractile responses induced by 120 mM KCl in aortic rings. (A) LmnaG609G/G609G
mice and wild-type controls (Lmna+/+). (B) LmnaLCS/LCSSM22αtg/+ mice and LmnaLCS/LCS controls.
Statistical differences were analyzed with two-way ANOVA followed by the Sidak multiple comparison
test. * p < 0.05; *** p < 0.001.
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3.3. Treatment with Sodium Nitrite Improves Vascular Function in Progeroid Mice
The key role of NO in progerin-induced endothelial dysfunction (Figure 2C) suggested that NO
supplementation might improve vascular tone regulation in progeroid mice. We therefore treated
LmnaG609G/G609G mice and Lmna+/+ controls with drinking water supplemented with sodium nitrite
(see Materials and Methods). Wire myography with isolated aortic rings showed that nitrite treatment
restored sensitivity to acethylcholine-induced aortic relaxation in progeroid aortic rings (Figure 5A, cf.
Figure 2A). Nitrite treatment had no effect on DEA-NO-induced endothelium-independent relaxation
in progerid or control mice (Figure 5B, cf. Figure 2B). Nitrite treatment also ameliorated the impaired
phenylephrine-dependent contraction in aortic rings from progeroid mice (Figure 5C, cf. Figure 1A).
In contrast, nitrite treatment did not normalize KCl-induced contraction, which remained significantly
lower in progeroid aortic rings control aortic rings than in vessels from Lmna+/+ controls (Figure 5B, cf.
Figure 1B). These results demonstrate that dietary supplementation with sodium nitrite can ameliorate
defective vascular tone regulation in progeroid mice.
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Figure 5. Sodium nitrite treatment improves vascular tone regulation in progeroid mice. Wire 
myography in thoracic aorta rings from 14-week-old LmnaG609G/G609G and wild-type mice (Lmna+/+) 
treated with sodium nitrite in drinking water for 6 weeks. (A) Endothelium-dependent vasodilation 
induced by acetylcholine. (B) Endothelium-independent vasodilation induced by diethylamine 
NONOate (DEA-NO). (C) Contraction induced by phenylephrine. (D) Contraction induced by KCl. 
Statistical differences were analyzed by two-way ANOVA with Bonferroni’s post-hoc test for 
acetylcholine, DEA-NO and phenylephrine data, and by two-tailed t-test for KCl data. * p < 0.05. 
4. Discussion 
Aging and associated CVD constitute a major sanitary, societal, and economic challenge [1]. It is 
therefore of utmost importance to extend knowledge of the cellular and molecular mechanisms 
underlying vascular aging in order to design more effective diagnostic tools, prevention strategies, 
and therapies to promote healthier aging. The investigation of vascular aging in humans is 
challenging due to the difficulty of organizing long follow-up longitudinal studies in large 
population cohorts, as well as inherent complexity of post-analysis due to the concurrence with aging 
of other confounding cardiovascular risk factors, such as hypercholesterolemia, diabetes, 
hypertension, and obesity [2–4]. These limitations can be circumvented by studying premature aging 
syndromes characterized by accelerated CVD but lacking other confounding risk factors [5,6]. 
The HGPS mouse models generated over the last decade are excellent tools for studying 
cardiovascular aging over a relatively short time frame and without the presence of confounding 
cofactors, enabling the identification of the cell types most susceptible to progerin-induced CVD 
[6,22]. In the present study, we investigated vascular tone regulation in three HGPS models. We 
found severe contractile impairment in LmnaG609G mice with ubiquitous progerin expression, which 
was also observed in LmnaLCS/LCSSM22αCretg/+ with VSMC-specific progerin expression, but not in 
LmnaLCS/LCSTie2Cretg/+ mice with EC-specific progerin expression. These findings identify VSMCs as 
the main cell type targeted by progerin to impair vessel contraction, consistent with our recent studies 
showing that VSMC-specific progerin expression is sufficient to fully recapitulate vascular alterations 
observed in mice with ubiquitous progerin expression, including vessel stiffness with inward 
remodeling; VSMC loss; increased collagen deposition and decreased transverse waving of elastin 
Figure 5. Sodium nitrite treat es vascular tone regulation in progeroid mice. Wire
myography in thoraci aorta rings from 14-week-old LmnaG60 /G609G and wild-type mice (Lmna+/+)
treated with sodium nitrite in drinki t f eeks. (A) Endothelium-d pendent vasodilation
induced by acetylcholine. ( ) t eliu -independent vasodilation induced by diethylamine
NONOate (DEA-NO). (C) Contraction induced by phenylephrine. (D) Contraction induced by
KCl. Statistical differences were analyzed by two-way ANOVA with Bonferroni’s post-hoc test for
acetylcholine, DEA-NO and phenylephrine data, and by two-tailed t-test for KCl data. * p < 0.05.
4. Discussion
Aging and associated constitute a major sanitary, societal, and economic challenge [1]. It
is therefore of utmost importance to extend knowledge of the cellular and molecular mechanisms
underlying vascular aging in order to design more effective diagnostic tools, prevention strategies,
and therapies to promote healthier aging. The investigation of vascular aging in humans is challenging
due to the difficulty of organizing long follow-up longitudinal studies in large population cohorts, as
well as inherent complexity of post-analysis due to the concurrence with aging of other confounding
Cells 2020, 9, 656 8 of 11
cardiovascular risk factors, such as hypercholesterolemia, diabetes, hypertension, and obesity [2–4].
These limitations can be circumvented by studying premature aging syndromes characterized by
accelerated CVD but lacking other confounding risk factors [5,6].
The HGPS mouse models generated over the last decade are excellent tools for studying
cardiovascular aging over a relatively short time frame and without the presence of confounding
cofactors, enabling the identification of the cell types most susceptible to progerin-induced CVD [6,22].
In the present study, we investigated vascular tone regulation in three HGPS models. We found severe
contractile impairment in LmnaG609G mice with ubiquitous progerin expression, which was also observed
in LmnaLCS/LCSSM22αCretg/+ with VSMC-specific progerin expression, but not in LmnaLCS/LCSTie2Cretg/+
mice with EC-specific progerin expression. These findings identify VSMCs as the main cell type
targeted by progerin to impair vessel contraction, consistent with our recent studies showing that
VSMC-specific progerin expression is sufficient to fully recapitulate vascular alterations observed in
mice with ubiquitous progerin expression, including vessel stiffness with inward remodeling; VSMC
loss; increased collagen deposition and decreased transverse waving of elastin layers in the medial
layer [25]; and accelerated atherosclerosis, medial LDL retention, and plaque vulnerability (when
examined in a proatherogenic Apoe−/− background) [26,27].
The defective vasoconstriction in progeroid mice reported here is in agreement with results
by others showing decreased vasoconstrictor responses in normally aged mice [40,41]. We recently
identified collagen deposition by VSMCs as a major contributor to vessel stiffness in LmnaG609G/G609G
mice [25]. We therefore hypothesized that progerin-dependent contractile impairment could be due to
mechanical impediment by a collagen stiff matrix, smooth muscle cell degeneration, or be caused by
a combination of both. Treatment of aortic rings with collagenase to disrupt collagen did not improve
contractile responses in LmnaG609G/G609G and LmnaLCS/LCSSM22αCretg/+ aortas, suggesting that collagen
deposition is not the cause of impaired vasoconstriction in these animals. VSMC degeneration and
dysfunction is therefore the most likely reason for contractile impairment, which might be the initiating
cause of progerin-induced collagen deposition and defective vasoconstriction in HGPS models.
Our results show that progeroid endothelial dysfunction requires simultaneous expression of
progerin in VSMCs and ECs, since progerin expression in VSMCs or ECs alone does not impair
acetylcholine-dependent vessel relaxation. Moreover, vessels from mice with EC-specific progerin
expression do not recapitulate the stiffness and inward remodeling observed in mice with ubiquitous
or VSMC-specific progerin expression [25]. These findings indicate that the endothelial dysfunction
observed in mice with ubiquitous progerin expression must be the result of systemic factors, or
that it requires the combination of a dysfunctional medial and endothelial layer. However, since
we have used a chemical signal to induce NO-dependent relaxation, we cannot rule out that other
mechanically driven signals relevant for endothelial-dependent relaxation might be affected by
EC-specific progerin expresion. Interestingly, transgenic mice with EC-specific overexpression of
human progerin exhibit interstitial myocardial and perivascular fibrosis without VSMC loss [42].
Excessive collagen production in these mice is primarily derived not from ECs directly but from
EC-dependent induction of a profibrotic response in the surrounding tissue [42]. HGPS patients show
no alterations to flow mediated dilation [7,11], an indirect measure of endothelial function; nevertheless,
the severe atherosclerosis in these patients must be preceded or accompanied by endothelial dysfunction
at some point. Indeed, endothelial dysfunction and vascular stiffness might be induced independently
but in parallel in HGPS, synergistically promoting vessel dysfunction and atherosclerosis as the
disease progresses.
Deficient NO bioavailability is known to cause endothelial dysfunction in various CVD settings
and in physiological aging [29,30]. In addition, mice overexpressing human progerin exclusively in ECs
have reduced eNOS expression and NO levels [42]. We recently reported that NO supplementation by
adding sodium nitrite to drinking water prevents vascular stiffness in progeroid mice [25]. In the present
study, we demonstrate that NO is the main driver of endothelial-dependent vasodilation in mice with
ubiquitous progerin expression and that treatment with sodium nitrite reverts endothelial dysfunction
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and partially ameliorates contractile impairment in progeroid mice. Nitrite supplementation increases
NO bioavailability without the requirement of L-arginine and NOS [43]. The beneficial effect of
sodium nitrite in phenylephrine-induced contractility we observed in progeroid aortic rings might be
related to an improvement in VSMC and EC homeostasis rather than to reduced vessel stiffness, since
treatment with collagenase to decrease vessel stiffness did not abrogate progerin-induced defects in
contractility. Future studies should examine whether the beneficial effect of nitrites on the contraction
of progeroid aortic rings can be also explained by local compensatory mechanisms, such as a shift in
NO/prostaglandin/EDHF balance.
In summary, our work demonstrates for the first time the presence of vascular tone abnormalities
such as a severe VSMC contractile impairment and endothelial dysfunction in a mouse model of
premature aging caused by ubiquitous progerin expression. VSMCs are the main cell type involved in
this contractile impairment, whereas neither VSMC-specific nor EC-specific progerin expression are
sufficient to provoke endothelial dysfunction, which likely requires progerin expression in both ECs
and VSMCs, and possibly also in other cell types. Our results also suggest dietary supplementation
with nitrites as a novel therapy to treat CVD in HGPS patients.
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